Clinical trials: Chronic Inflammatory Disease
Pulmonary Disease, Chronic Obstructive
Prednisolone Novel Endpoint Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Prednisolone will be used as a model medication to identify new clinical outcomes for future evaluation of new therapies in short-term studies (up to 4 weeks) in patients with Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT00379730
- Testing
- Prednisolone
- Where
- 5 sites in Argentina, Chile and 2 more
- Volunteers
- 90 people
- Sponsor
- GlaxoSmithKline
Chronic Inflammatory Demyelinating Polyneuropathy, CIDP
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
The main purpose of this study is to compare empasiprubart and IVIg for treating people with CIDP. This study consists of a Part A where participants will either receive empasiprubart and a placebo resembling IVIg, or IVIg and a…
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
- Trial name
- emvigorate (NCT06920004)
- Testing
- empasiprubart, IVIg
- Where
- 103 sites in United States, Argentina and 29 more
- Volunteers
- 218 people
- Sponsor
- argenx
Asthma Bronchiale, Bronchiectasis
A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Airway Mucus Hypersecretion
This is a phase II, randomised, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of HSK31858 in patients with airway mucus hypersecretion in chronic airway inflammatory diseases
- Conditions
- Asthma Bronchiale, Bronchiectasis, Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT06820749
- Testing
- HSK31858
- Where
- China
- Volunteers
- 309 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Chronic Graft-versus-host Disease (cGVHD)
A Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AMG 592 in Healthy Participants
The primary objective of this study is to evaluate the safety, tolerability and immunogenicity profile of single and multiple dose administrations of AMG 592 in healthy participants.
- Trial name
- NCT05873907
- Testing
- AMG 592
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Amgen
Chronic Inflammatory Disorder, Arthritis, Rheumatoid
A Relative Bioavailability and Food Effect Study of New Formulations
The purpose of this trial is to assess the effect of 3 formulations on the relative bioavailability of LY3009104. Participants will receive single dose of LY3009104 on 4 separate occasions with and without food.
- Trial name
- NCT01398475
- Testing
- LY3009104
- Where
- Singapore
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Arthritis, Rheumatoid, Spondylitis, Ankylosing
Post Marketing Surveillance Study of Remicade in Patients With Chronic Inflammatory Diseases (P04840)
This study will be performed to evaluate and document the safety and efficacy of infliximab (Remicade®) in the treatment of chronic inflammatory diseases in big cohorts in the daily routine practice of rheumatologists…
- Conditions
- Arthritis, Rheumatoid, Spondylitis, Ankylosing, Arthritis, Psoriatic, Psoriasis
- Trial name
- REMission (NCT00727298)
- Testing
- Infliximab
- Volunteers
- 4,485 people
- Sponsor
- Merck Sharp & Dohme LLC
Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome
Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
This trial will provide long-term safety, efficacy and tolerability of ACZ885 in CAPS patients that completed the CACZ885D2307 study
- Conditions
- Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease
- Trial name
- NCT01576367
- Testing
- ACZ885
- Where
- 12 sites in Belgium, Canada and 5 more
- Volunteers
- 17 people
- Sponsor
- Novartis Pharmaceuticals
Healthy
PH-797804 LPS Study in Healthy Volunteers
The study was performed to assess the effect of PH-797804 on neutrophils (white cells) in the sputum after a challenge with an endotoxin (inhaled LPS).
- Trial name
- NCT02084485
- Testing
- PH-797804
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Chronic Inflammatory Demyelinating Polyneuropathy
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This is a Phase 2b study to evaluate the efficacy and safety of Imeroprubart in adults with CIDP.
- Trial name
- NCT07032662
- Testing
- Imeroprubart
- Where
- 142 sites in United States, Argentina and 28 more
- Volunteers
- 162 people
- Sponsor
- Immunovant Sciences GmbH
Moderate to Severe Plaque-type Psoriasis
Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab
This was an extension study of secukinumab prefilled syringes in subjects with moderate to severe chronic plaque-type psoriasis completing preceding psoriasis phase III studies with secukinumab.
- Trial name
- NCT01544595
- Testing
- Secukinumab (AIN457)
- Where
- 182 sites in United States, Argentina and 24 more
- Volunteers
- 1,147 people
- Sponsor
- Novartis Pharmaceuticals
Antiphospholipid (aPL)-Positive, Rheumatic Arthritis
MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)
The primary objective of this multicenter observational registry is to characterize the clinical, epidemiological, and biological profiles of individuals of Middle Eastern, North African, and Levantine ancestry, including…
- Conditions
- Antiphospholipid (aPL)-Positive, Rheumatic Arthritis, Celiac Disease, Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- MERIT (NCT07892651)
- Where
- Jordan
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Axiom Bioregistry
Eyes Dry Chronic, Chronic Conjunctivitis of Both Eyes
CDL Validation Study
Ocular surface photography is significantly limited in standardization and reproducibility. This reduces its applicability for clinical monitoring of acute or chronic disease.
- Conditions
- Eyes Dry Chronic, Chronic Conjunctivitis of Both Eyes, Limbal Stem-cell Deficiency, Eye Lesion
- Trial name
- NCT05461469
- Where
- Austria
- Volunteers
- 104 people
- Sponsor
- Occyo GmbH
Systemic Lupus Erythematosus, Rheumatoid Arthritis
Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)
The ImmuneNet study is a Phase I/II clinical trial sponsored by Truway Health, Inc. It will test whether gentle, low-frequency electromagnetic resonance (LF-EMR) can influence how immune cells communicate and synchronize with…
- Conditions
- Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Autoimmune Diseases
- Trial name
- QSIT (NCT07221565)
- Testing
- Low-Frequency Electromagnetic Resonance Therapy (LF-EMR), Low-Dose Naltrexone (LDN)
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Truway Health, Inc.
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
The purpose of the study is to assess long-term safety and tolerability of weekly doses of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
- Trial name
- NCT04051944
- Testing
- Rozanolixizumab
- Where
- 14 sites in United States, Belgium and 6 more
- Volunteers
- 21 people
- Sponsor
- UCB Biopharma SRL
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)
This Post Trial Access (PTA) Program enables access to rozanolixizumab for eligible patients who have taken part in the CIDP04 trial (NCT04051944) and are continuing to derive benefit from treatment.
- Trial name
- NCT05014724
- Testing
- Rozanolixizumab
- Sponsor
- UCB Biopharma SRL
Arthritis, Psoriatic
16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis
The purpose of this study was to provide 16-week efficacy, safety and tolerability data versus placebo to support the use of secukinumab 150 mg by subcutaneous (s.c.) self-administration with or without a loading regimen and…
- Trial name
- FUTURE 4 (NCT02294227)
- Testing
- Secukinumab
- Where
- 64 sites in United States, Australia and 11 more
- Volunteers
- 341 people
- Sponsor
- Novartis Pharmaceuticals
Acute Gouty Arthritis
Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney Disease
The purpose of this study is to confirm the efficacy and safety results obtained in a chronic kidney disease (CKD) subgroup of patients participating in Phase III studies in a larger, independent patient population with difficult…
- Trial name
- NCT01593527
- Testing
- ACZ885, Triamcinelone acetonide
- Sponsor
- Novartis Pharmaceuticals
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
The aim of this study is to learn more about the following treatment options in adults with CIDP: Subcutaneous self-infusion with HyQvia. Intravenous infusion with Gammagard/Kiovig.
- Trial name
- NCT02549170
- Testing
- HYQVIA, IGIV GAMMAGARD LIQUID/KIOVIG, IGIV GAMUNEX®-C
- Where
- 83 sites in United States, Argentina and 20 more
- Volunteers
- 138 people
- Sponsor
- Baxalta now part of Shire
Intestinal Disease
Study of the Prevalence of Iron Deficiency in Patients With Chronic Inflammatory Bowel Disease
Despite its known prevalence in IBD, a recent study conducted with Prof. Cacoub (unpublished) on the national health insurance database showed that iron deficiency was an under-diagnosed and under-treated co-morbidity.
- Trial name
- NCT04123990
- Testing
- Iron status testing
- Volunteers
- 1,100 people
- Sponsor
- VIFORFRANCE
Ulcerative Colitis, Ulcerative Colitis Chronic
A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis
A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will have 4 periods and will last for 36 weeks.
- Trial name
- LUCENT-URGE (NCT05767021)
- Testing
- Mirikizumab
- Where
- 120 sites in United States, Belgium and 8 more
- Volunteers
- 172 people
- Sponsor
- Eli Lilly and Company